Clinical trials: HIV-associated Neurocognitive Dysfunction
HIV Associated Cognitive Motor Complex
Effect of Galantamine on Inflammation and Cognition
This study tests whether galantamine (GAL) reduces HIV-related inflammation and cognitive deficits. In this double-blind placebo-controlled crossover study, HIV-infected individuals (N=120; 60 smokers and 60 non-smokers) will be…
- Trial name
- CHI (NCT03384784)
- Testing
- Galantamine
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- University of Pennsylvania
HIV-associated Neurocognitive Dysfunction
Cognitive Remediation for HIV-associated Neurocognitive Dysfunction
This study is a validation study to document the acceptability of the revised Plasticity-based Adaptive Cognitive Remediation (PACR) program to patients with HIV-associated Neurocognitive Dysfunction (HAND).
- Trial name
- HAND (NCT02671526)
- Testing
- Computerized plasticity-based adaptive cognitive training
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Posit Science Corporation
Human Immunodeficiency Virus (HIV), HIV Associated Neurocognitive Disorders (HAND)
A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIV
HIV related cognitive impairment still occurs despite highly active antiretroviral therapy (HAART). HIV disease affects the brain in 20-40% of patients with advancing HIV disease leading to varying degrees of cognitive…
- Trial name
- HANDral (NCT01448486)
- Testing
- Raltegravir
- Where
- 2 sites in Australia
- Volunteers
- 6 people
- Sponsor
- St Vincent's Hospital, Sydney
HIV Infections
Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)
People infected with HIV often have cognitive dysfunction even if they are on antiretroviral therapy (ART) and have undetectable viral loads.
- Trial name
- NCT02519777
- Testing
- Dolutegravir (DTG), Maraviroc (MVC)
- Where
- 30 sites in United States, Brazil and 3 more
- Volunteers
- 191 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hiv, Neurocognitive Dysfunction
Using Less Neurotoxic Drugs in Patients With HAND (MARAND-X)
Neurocognitive disorders are still highly prevalent in the HAART era; despite a dramatic reduction in dementia cases, 15-50% of patients may develop mild or asymptomatic neurocognitive disorders (HIV-associated neurocognitive…
- Trial name
- (MARAND-X) (NCT03163277)
- Testing
- emtricitabine, darunavir/cobicistat, maraviroc
- Where
- Italy
- Volunteers
- 38 people
- Sponsor
- Giovanni Di Perri
HIV Infections
Minocycline for the Treatment of Decreased Mental Function in HIV-Infected Adults
The purpose of this study is to determine the effectiveness of minocycline, an antibiotic, in lessening the decreased mental function sometimes caused by anti-HIV drugs.
- Trial name
- NCT00361257
- Testing
- Minocycline
- Where
- 16 sites in United States
- Volunteers
- 107 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
HIV - Human Immunodeficiency Virus, Cognitive Impairment
Cognitive Training for the Remediation of Functional Brain Health in HIV
Cognitive deficits in HIV reflect degraded brain network functioning that may be amenable to remediation through cognitive training.
- Trial name
- NCT02571504
- Testing
- Plasticity-based Adaptive Cognitive Remediation (PACR)
- Where
- Canada
- Volunteers
- 81 people
- Sponsor
- McGill University
HIV Associated Neurocognitive Disorder, HIV Dementia
SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy
The purpose of this study is to longitudinally characterize and evaluate changes in synaptic density in the brain using novel positron-emission tomography (PET) scans; magnetic resonance imaging (MRI), and clinical laboratory…
- Conditions
- HIV Associated Neurocognitive Disorder, HIV Dementia, HIV Encephalitis, Healthy
- Trial name
- ART (NCT05586581)
- Testing
- SV2A PET, TSPO PET
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Yale University
HIV-associated Cognitive Impairment, HIV Infections
Minocycline for HIV+ Cognitive Impairment in Uganda
Purpose: The purpose of the study is to assess the safety and effectiveness of minocycline, an antibiotic, in the treatment of Human immunodeficiency virus (HIV)-associated cognitive impairment in Uganda.
- Trial name
- NCT00855062
- Testing
- minocycline
- Where
- Uganda
- Volunteers
- 73 people
- Sponsor
- Johns Hopkins University
Mild Cognitive Impairment (MCI), Alzheimer Disease (AD)
Biomarkers in Neurodegenerative Diseases
The general purpose of this observational study is to examine biomarkers associated with the pathology of neurodegenerative diseases to potentially develop novel therapeutic approaches.
- Conditions
- Mild Cognitive Impairment (MCI), Alzheimer Disease (AD), Dementia With Lewy Bodies (DLB), Frontotemporal Lobar Degeneration (FTLD)
- Trial name
- NCT04055532
- Testing
- Neuraceq
- Where
- United States
- Sponsor
- University of Minnesota
Impaired Cognition, HIV Infection
Mindfulness Based Stress Reduction for Older Adults With HIV Associated Neurocognitive Disorders
The purpose of this study is to determine the efficacy of Mindfulness Based Stress Reduction (MBSR) to alleviate stress, anxiety, and depressive symptoms, and improve attention among patients aged 60 or older who suffer from…
- Trial name
- NCT02936401
- Testing
- MBSR
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- University of California, San Francisco
Cognition Disorders, HIV Infections
Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients
A decrease in mental function often occurs in patients with HIV. Antiretroviral (ARV) drugs are used to treat this but are not entirely effective. Some other therapy could play a role.
- Trial name
- NCT00013585
- Testing
- Selegiline hydrochloride
- Where
- 15 sites in United States
- Volunteers
- 127 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-Associated Cognitive Motor Complex, Aging
Individualized Cognitive Training in HIV
Over 50% of adults with HIV have some form of HIV-Associated Neurocognitive Disorder (HAND) which represents a significant symptom that interferes with everyday functioning and quality of life.
- Conditions
- HIV-Associated Cognitive Motor Complex, Aging, Cognitive Impairment, Cognitive Decline
- Trial name
- TOPS (NCT03122288)
- Testing
- Individualized Cognitive Training, No-Contact Control
- Where
- United States
- Volunteers
- 109 people
- Sponsor
- University of Alabama at Birmingham
HIV/AIDS, Aging
Psychosocial Intervention for Older HIV+ Adults With HAND
CTNPT 029 will test the feasibility and acceptability of cognitive remediation group therapy in older adults living with HIV who have been diagnosed with HIV-associated neurocognitive disorder (HAND).
- Conditions
- HIV/AIDS, Aging, Mild Cognitive Impairment, Group, Peer
- Trial name
- IN-HAND (NCT03483740)
- Testing
- CRGT, HIV group therapy
- Where
- 3 sites in Canada
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Human Immunodeficiency Virus (HIV), HIV Associated Neurocognitive Disorders (HAND)
A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac)
HIV related cognitive impairment still occurs despite highly active antiretroviral therapy (HAART). HIV disease affects the brain in 20-40% of patients with advancing HIV disease; leading to varying degrees of cognitive…
- Trial name
- HANDmac (NCT01449006)
- Testing
- Maraviroc
- Where
- 2 sites in Australia
- Volunteers
- 19 people
- Sponsor
- Bruce Brew
HIV, Aging
The Targeted Neurocognitive Training (TNT) Study
People with HIV (PWH) often suffer from cognitive impairments known as HIV-Associated Neurocognitive Disorder (HAND). Cognitive impairments in PWH are not fully captured by traditional neurocognitive assessment; thus, we must…
- Conditions
- HIV, Aging, Cognitive Function Abnormal, Cognitive Training
- Trial name
- TNT (NCT05773430)
- Testing
- Targeted Neurocognitive Training
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
HIV-1-infection, Aging, Premature
Mental Ability Challenge Study in Adults With and Without HIV
It is estimated that by 2016, nearly 50% of HIV-positive individuals in the US will be aged 50 or older, and up to 60% of those will experience some degree of cognitive impairment as they age.
- Conditions
- HIV-1-infection, Aging, Premature, Cognitive Impairment, Memory Impairment
- Trial name
- NCT03244488
- Testing
- Scopolamine Injectable Product, Mecamylamine Pill
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Cognitive Disorders, HIV Infections
A Study of Decreased Mental Function Associated With HIV
The purpose of this study is to compare pictures of the brain of HIV-infected people with memory problems before and after treatment with selegiline. Selegiline is the study drug received through A5090.
- Trial name
- NCT00027040
- Testing
- Selegiline hydrochloride
- Where
- 12 sites in United States
- Volunteers
- 90 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)